Source comparison
MK-677 Science Explained: Mechanism Comparison
Understanding how MK-677 differs mechanistically from other growth hormone modulation strategies is critical for researchers designing experimental protocols. The table below compares MK-677 to exogenous growth hormone, traditional peptide secretagogues, and G
This comparison does not assign a generated winner or score.
- Understanding how MK-677 differs mechanistically from other growth hormone modulation strategies is critical for researchers designing experimental protocols. The table below compares MK-677 to exogenous growth hormone, traditional peptide secretagogues, and GHRH analogs across key pharmacological and practical dimensions.
- MK-677 (ghrelin receptor agonist)
- Oral capsule or liquid
- 4–6 hours (effects last 24 hours)
- Yes. Amplifies natural pulses without flattening
- No desensitization observed in trials up to 12 months
- Ideal for long-term research requiring stable IGF-1 elevation and simplified administration
- Exogenous GH (somatropin)
- Subcutaneous injection
- 3–4 hours
- No. Replaces natural secretion with continuous exogenous supply
- N/A. Replaces rather than stimulates
- Gold standard for GH replacement but suppresses endogenous production
- Peptide secretagogues (GHRP-6, hexarelin)
- 20–30 minutes
- Yes initially, but requires multiple daily doses to sustain
- Moderate. Receptor sensitivity declines after 8–12 weeks
- Effective for acute GH pulse amplification but limited by desensitization and injection frequency
- GHRH analogs (sermorelin, CJC-1295)
- Sermorelin: 10–20 min; CJC-1295 (DAC): 6–8 days
- Yes. Stimulates natural pulsatile release at GHRH receptor
- Moderate. Chronic use can lead to GHRH receptor downregulation
- Strong for preserving pulsatility; DAC variants reduce injection frequency but carry desensitization risk